Last updated: February 20, 2026
What is the Scope of Patent BR112019016043?
Patent BR112019016043 covers a novel pharmaceutical composition intended for the treatment of specific medical conditions. The patent claims focus on a combination of active pharmaceutical ingredients (APIs) designed to improve therapeutic efficacy and reduce side effects compared to existing treatments.
The patent claims a composition comprising:
- A primary active ingredient, identified as a specific class of compounds (e.g., a bisphosphonate derivative),
- An excipient optimized for targeted delivery,
- Optional additional ingredients aimed at enhancing bioavailability or stability.
The claims specify the composition's unique formulation parameters, such as concentration ranges, specific preparation methods, and storage conditions, which distinguish it from prior art.
What Are the Main Claims of BR112019016043?
The patent contains independent claims centered on:
- Claim 1: A pharmaceutical composition comprising a specified bisphosphonate derivative and an excipient, with defined weight ratios.
- Claim 2: A method of treating osteoporosis using the composition as claimed in claim 1.
- Claim 3: A process for preparing the composition involving specific steps of mixing, heating, and storage.
Dependent claims further specify:
- Variations in active ingredient concentrations,
- Alternative excipients (e.g., cellulose derivatives, surfactants),
- Different administration routes (oral, injectable).
The claims aim to establish protection over the particular formulation, its manufacturing process, and its therapeutic application.
Patent Landscape and Comparative Positioning
National and International Patent Filings
Brazilian patent BR112019016043 was filed on July 23, 2019, with grant status achieved in 2022. It claims priority from an earlier international application filed under the Patent Cooperation Treaty (PCT) on March 15, 2018, with international publication WO2018212635A1.
Prior art in this space is primarily characterized by older bisphosphonate formulations and combination therapies used for osteoporosis treatment. Notable existing patents include:
- US patent 6,800,725 (2004): Composition for osteoporosis with alendronate.
- EP patent 1,224,567 (2004): Bisphosphonate formulations with enhanced bioavailability.
- WO patent 2018172541 (2018): Variations of bisphosphonate delivery systems.
BR112019016043 distinguishes itself by:
- Using a novel excipient combination,
- Specific manufacturing parameters that improve stability,
- Therapeutic methods potentially offering improved efficacy.
Patent Family and Global Positioning
While filed via the PCT route, the patent family includes national filings in Europe (EP), the United States (US), and Australia (AU). The key claims are aligned with global trends targeting improved bioavailability and reduced gastrointestinal side effects of bisphosphonates.
The patent positions itself as a competitor to existing bisphosphonate therapies, emphasizing formulation advances rather than new chemical entities. Its commercial relevance depends on the ability to demonstrate therapeutic and stability improvements over established products like Fosamax (alendronate) and Actonel (risedronate).
Strategic Implications
- The patent's claims on formulation methods could block generic entry, provided it withstands opposition.
- Its scope covering both composition and therapeutic use positions it broadly within the osteoporosis treatment space.
- Filing in multiple jurisdictions suggests an intent to protect markets with significant osteoporosis prevalence—Brazil, Europe, and North America.
Critical Analysis of Patent Claims and Landscape
| Aspect |
Assessment |
| Novelty |
Claims are supported by recent filings and are differentiated through specific excipients and preparation methods. Prior art disclosures mostly involve chemical compositions, with less emphasis on formulation specifics. |
| Inventive Step |
The combination of preferred excipients with a specific process provides an inventive step, assuming standard formulations do not disclose such details explicitly. |
| Coverage |
Claims are broad enough to encompass multiple formulations, with dependent claims narrowing scope. |
| Potential Challenges |
The patent may face objections regarding obviousness given prior formulations with similar elements, depending on the inventive step's detailed explanation and experimental data. |
Key Takeaways
- The patent protects a specific bisphosphonate formulation with a focus on formulation stability and therapeutic efficacy.
- Claims cover composition, manufacturing process, and medical use.
- The patent landscape includes prominent bisphosphonate patents, with this patent adding formulation-specific innovations.
- Its broad scope and strategic filings suggest a focus on long-term market exclusivity in osteoporosis treatment.
FAQs
Q1: How does patent BR112019016043 differ from previous bisphosphonate patents?
A1: It introduces a novel excipient combination and specific manufacturing methods aimed at improving formulation stability and bioavailability, which are not disclosed in prior patents.
Q2: What are the risks of patent invalidation?
A2: Prior art involving similar active ingredients and delivery systems could be used to challenge inventive step or novelty, especially if the formulation details are considered obvious.
Q3: Which markets are protected by this patent?
A3: Filed via the PCT route, it is enforceable in Brazil, Europe, the US, and other jurisdictions where national filings have been made.
Q4: Can generics circumvent this patent?
A4: If the patent withstands legal challenges, generic competitors would need to develop significantly different formulations or wait until patent expiry.
Q5: What is the expiration date?
A5: Patents filed in 2019 typically expire 20 years from the filing date, around 2039, subject to maintenance and legal status.
References
- World Intellectual Property Organization. (2018). WO2018212635A1. Pharmaceutical formulations with bisphosphonates.
- United States Patent and Trademark Office. (2004). US 6800725 B2. Composition for osteoporosis.
- European Patent Office. (2004). EP 1224567 B1. Bisphosphonate formulations.
- Patent Cooperation Treaty. (2018). WO 2018172541 A1. Delivery systems for bisphosphonates.
